Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Sana Biotechnology Inc — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $91.17 (market cap $12.87B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: iShares JPMorgan USD Emerging Markets Bond ETF is far larger — about 15.4× Sana Biotechnology Inc's market cap, and iShares JPMorgan USD Emerging Markets Bond ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares JPMorgan USD Emerging Markets Bond ETF for 51 Days and Sana Biotechnology Inc for 23 Days on average.
| EMB | SANA | |
|---|---|---|
Market Cap | $12.87B | $836.71M |
Volume | 14,946,002 | 4,507,444 |
Sector | Fixed Income | Health |
52-Week High | $97.74 | $5.92 |
52-Week Low | $90.14 | $2.68 |
Typical Hold Time | 51 Days | 23 Days |
Enterprise Value | — | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB stock trades at $90.96, up 0.2% on the day, with a bearish technical signal from moving averages and mixed oscillators. The company has announced several upcoming dividends in late 2026. Recent news highlights broader market risks from rising bond yields and a focus on income generation from fixed-income assets.
The outlook for EMB is cautious, with technical indicators suggesting near-term pressure. Investment opportunity hinges on its income profile via dividends, but limited fundamental data and bearish sentiment pose risks. Investors should weigh the income potential against market volatility and sparse public financial disclosures.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
